Rheumatoid Arthritis Treatment Market By Drugs Type (Non-Steroidal anti-inflammatory Drugs (NSAIDs), Corticosteroids, Disease modifying anti-rheumatic drugs (DMARDs)), By Treatment (Synovectomy, Tendon Repair, Joint Fusion), By End User (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers), and Geography

 

Rheumatoid Arthritis Treatment Market size was valued at USD 22.9 billion in 2021, growing at a CAGR of 4.6% from 2022-28.  This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global rheumatoid arthritis treatment products. The World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of worldwide significance on January 30, 2020. Around 210 countries have been affected by COVID-19. Patients with rheumatoid arthritis who contract COVID-19 infection, according to the Lancet Rheumatology 2020, are at a high risk of developing severe symptoms and further consequences.Many DMARDs are in wide adoption as a first-line treatment for rheumatoid arthritis, such as sulphasalazine, methotrexate and hydroxychloroquine. Major companies like Can-Fite BioPharma Ltd. are investigating several novel antirheumatic disease modifying agents that are expected to be available in the market in the next 10 years, uptake of which by prescribers and patients would push market growth.